Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.3.315

Phenotype-genotype correlations and the efficacy of growth hormone treatment in Korean children with Prader-Willi syndrome  

Bae, Keun Wook (Department of Pediatrics, Asan Medical Center University of Ulsan College of Medicine)
Ko, Jung Min (Department of Pediatrics, Asan Medical Center University of Ulsan College of Medicine)
Yoo, Han Wook (Medical Genetics Clinic and Laboratory, Asan Medical Center University of Ulsan College of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.3, 2008 , pp. 315-322 More about this Journal
Abstract
Purpose : Prader-Willi syndrome (PWS) is a complex genetic disorder, caused by the deletion of the paternally derived 15q11-13 region or the maternal uniparental disomy of chromosome 15 (mUPD(15)). In this study, we compared phenotypic differences between those patients whose disease was caused by microdeletion and those caused by mUPD(15). In addition, a comparison of the efficacy of growth hormone (GH) therapy between these two PWS genotypes was analyzed. Methods : Fifty-three patients were diagnosed as having PWS based on molecular and cytogenetic analyses and clinical features. Data that included maternal age, birth weight, a feeding problem in the neonatal period, cryptorchidism, developmental delay or mental retardation, short stature, hypopigmentation, changes in height, weight, and body mass indexes (BMI) before and after GH treatment were obtained by a retrospective review of medical records. The data from the patients with microdeletion were compared with those from the patients with mUPD(15). Results : Of the 53 patients with genetically confirmed PWS, 39 cases had microdeletion and 14 mUPD(15). Maternal ages were significantly higher in the mUPD(15) group, and hypopigmentation and a feeding problem in the neonatal period were more frequent in the microdeletion group. Growth hormone was administered to 20 patients [14 with microdeletion, 6 with mUPD(15)]. There were no differences between the two groups in height velocity, weight and height SDS, and BMI after GH therapy. Conclusion : Phenotype and genotype correlations were observed in Korean PWS patients, such as more advanced maternal ages in the mUPD(15) group and more feeding problems and hypopigmentations in the microdeletion group. Further long-term prospective studies are needed to correlate other aspects of the phenotypes.
Keywords
Prader-Willi syndrome; Phenotype-genotype correlation; Microdeletion; Uniparental disomy; Growth hormone;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993;91:398-402
2 Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 2004;15:12-20   DOI   ScienceOn
3 Cassidy SB, Schwartz S. Prader-Willi and Angelman syndromes: disorders of genomic imprinting. Rev Mol Med 1998;77:140-51   DOI   ScienceOn
4 Webb T, Whittington J, Clarke D, Boer H, Butler J, Holland A. A study of the influence of different genotypes on the physical and behavioral phenotypes of children and adults ascertained clinically as having PWS. Clin Genet 2002;62: 273-81   DOI   ScienceOn
5 Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, Roberts S, et al. Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 2005:46:1089-96   DOI   ScienceOn
6 Varela MC, Kok F, Setian N, Kim CA, Koiffmann CP. Impact of molecular mechanisms, including deletion size, on Prader-Willi syndrome phenotype: study of 75 patients. Clin Genet 2005;67:47-52   DOI   ScienceOn
7 Lee JE, Moon KB, Hwang JH, Kwon EK, Kim SH, Kim JW, et al. Clinical characteristics and genetic analysis of Prader-Willi syndrome. J Korean Pediatr Soc 2002:45:1126-33
8 Rinchik EM, Bultman SJ, Horsthemke B, Lee ST, Strunk KM, Spritz RA, et al. A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 1993;361:72-6   DOI   ScienceOn
9 Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5   DOI
10 Prader A, Labhart A, Willi H. Ein syndrom von Adipositias, Kleinwuchs, Kryptorchismus und Oligophrenie nach myoto-nieartigem Zustandim Neugeborenenalter. Schweiz Med Wochenschr 1956;86:1260-1
11 Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin Endocrinol (Oxf ) 1998;48:769-75   DOI   ScienceOn
12 Swaab DF. Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 1997;423:50-4
13 Park JE, Lee SW, Song KE, Lee HS, Kim DJ, Chung YS, et al. Growth hormone treatment in Prader-Willi syndrome. J Korean Soc Endocrinol 2006;21:40-6   DOI   ScienceOn
14 Ginsburg C, Fokstuen S, Schinzel A. The contribution of uniparental disomy to congenital development defects in children born to mothers at advanced childbearing age. Am J Med Genet 2000;95:454-60   DOI   ScienceOn
15 Torrado M, Araoz V, Baialardo E, Abraldes K, Mazza C, Krochik G, et al. Clinical-etiologic correlation in children with Prader-Willi syndrome (PWS): an interdisciplinary study. Am J Med Genet A 2007;143:460-8
16 Miller SP, Riley P, Shevell MI. The neonatal presentation of Prader-Willi syndrome revisited. J Pediatr 1999;134:226-8   DOI   ScienceOn
17 Shin HJ, Kim DH. Effects of growth hormone therapy in Prader-Willi syndrome. J Korean Soc Pediatr Endocrinol 2000;5:52-9
18 Paterson WF, Donaldson MD. Growth hormone therapy in the Prader-Willi syndrome. Arch Dis Child 2003;88:283-5   DOI
19 Robinson WP, Bottani A, Xie YG, Balakrishman J, Binkert F, Marhler M, et al. Molecular, cytogenetic, and clinical investigations of Prader-Willi syndrome patients. Am J Hum Genet 1991;49:1219-34
20 Nativio DG. The genetics, diagnosis, and management of Prader-Willi syndrome. J Pediatr Health Care 2002;16:298-303   DOI
21 Gunay-Aygun M, Heeger S, Schwartz S, Cassidy SB. Delayed diagnosis in patients with Prader-Willi syndrome due to maternal uniparental disomy 15. Am J Med Genet 1997:71;106-10   DOI   ScienceOn
22 Obata K, Sakazume S, Yoshino A, Murakami N, Sakuta R. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2003;16:155-62
23 Roof E, Stone W, MacLean W, Feurer ID, Thompson T, Butler MG. Intellectual characteristics of Prader-Willi syndrome: comparison of genetic subtypes. J Intellect Disabil Res 2000:44:25-30   DOI   ScienceOn
24 Kim DS, Shin YL, Ko TS, Seo EJ, Y 00 HW. A study of Prader-Willi syndrome and Angelman syndrome with the deletion of same loci in 15 chromosome. J Korean Child Neurol Soc 2002;10:226-34
25 Eiholzer U, Lallemand D, Schlumpf M, Rousson V, Gasser T, Fusch C. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004;144:753-8
26 Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004;145:744-9   DOI   ScienceOn
27 Mitchell J, Schinzel A, Langlois S, Gillessen-Kaesbach G, Schuffenhauer S, Michaelis R, et al. Comparison of phenotype in uniparental disomy and deletion Prader-Willi syndrome: sex specific differences. Am J Med Genet 1996;65:133-6   DOI   ScienceOn
28 Gillessen-Kaesbach G, Robinson W, Lohmann D, KayaWesterloh S, Passarge E, Horsthemke B. Genotype-phenotype correlation in a series of 167 deletion and non-deletion patients with Prader-Willi syndrome. Hum Genet 1995;96:638-43   DOI
29 Gardner JM, Nakatsu Y, Gondo Y, Lee S, Lyon MF, King RA, et al. The mouse pink-eyed dilution gene: association with human Prader-Willi and Angelman syndromes. Science 1992;257:1121-4   DOI   ScienceOn
30 Thacker MJ, Hainline B, St Dennis-Feezle L, Johnson NB, Pescovitz OH. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998; 49:216-20   DOI   ScienceOn
31 Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 2007;143:443-8
32 Cassidy SB, Forsythe M, Heeger S, Nicholls RD, Schork N, Benn P, et al. Comparison of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am J Med Genet 1997:68;433-40   DOI   ScienceOn
33 Gunay-Aygun M, Schwartz S, Heeger S, ORiordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001;108:E92   DOI   ScienceOn
34 Dykens EM, Cassidy SB, King BH. Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy. Am J Ment Retard 1999;104:67-77   DOI   ScienceOn